SCHEMBL500447

SCHEMBL500447

CCCCC(=O)NC1(C(=O)O)CCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 2/20 0.49
EPHX2 P34913 2/20 0.42
CNR2 P34972 3/20 0.41
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
FAAH O00519 2/20 0.38
MAPK1 P28482 1/20 0.38
CTSB P07858 2/20 0.37
CTSS P25774 1/20 0.37
HSP90AA1 P07900 1/20 0.37
CTSL P07711 1/20 0.37
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9671904 0.98 SPHK1 (0.48) SPHK1EPHX2CNR2CYP4F2CYP4A11
SCHEMBL15297852 0.86 SPHK1 (0.65) SPHK1EPHX2MEN1KMT2AFAAH
SCHEMBL15297190 0.86 SPHK1 (0.65) SPHK1EPHX2MEN1KMT2AFAAH
SCHEMBL15285134 0.86 SPHK1 (0.65) SPHK1EPHX2MEN1KMT2AFAAH
SCHEMBL1131711 0.84 SPHK1 (0.55) SPHK1EPHX2MEN1KMT2AFAAH
SCHEMBL8485391 0.81 CNR2 (0.39) CNR2CYP4F2CYP4A11CTSBCTSS
SCHEMBL6840056 0.80 SPHK1 (0.44) SPHK1EPHX2MEN1KMT2AFAAH
SCHEMBL27760068 0.78 SPHK1 (0.52) SPHK1EPHX2CNR2MEN1KMT2A
SCHEMBL29242051 0.78 EPHX2 (0.45) SPHK1EPHX2CNR2MEN1KMT2A
SCHEMBL13146756 0.78 EPHX2 (0.45) SPHK1EPHX2MEN1KMT2AFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113933414-B Method for detecting organic impurities in amlodipine besylate composite preparation 株洲千金药业股份有限公司 2023-07-07 CN claimed
CN-113933414-A Method for detecting organic impurities in irbesartan amlodipine besylate composite preparation 株洲千金药业股份有限公司 2022-01-14 CN claimed
US-8106216-B2 Process for the preparation of Irbesartan AUROBINDO PHARMA LTD. (IN) 2012-01-31 US claimed
US-20100056797-A1 Process for the Preparation of Irbesartan AUROBINDO PHARMA LTD (IN) 2010-03-04 US claimed
WO-2007122508-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF IRBESARTAN AUROBINDO PHARMA LIMITED (IN) 2007-11-01 WO claimed
CN-118852127-B Method for removing impurities in irbesartan 浙江弘盛药业有限公司 2025-04-15 CN disclosed
CN-118852127-A Method for removing impurities in irbesartan 浙江弘盛药业有限公司 2024-10-29 CN disclosed
CN-113933414-B Method for detecting organic impurities in amlodipine besylate composite preparation 株洲千金药业股份有限公司 2023-07-07 CN disclosed
CN-113933414-A Method for detecting organic impurities in irbesartan amlodipine besylate composite preparation 株洲千金药业股份有限公司 2022-01-14 CN disclosed
US-8106216-B2 Process for the preparation of Irbesartan AUROBINDO PHARMA LTD. (IN) 2012-01-31 US disclosed
US-8106216-B2 Process for the preparation of Irbesartan AUROBINDO PHARMA LTD. (IN) 2012-01-31 US disclosed
WO-2010079405-A3 AN IMPROVED PROCESS FOR PREPARING 1-(PENTANOYLAMINO)CYCLOPENTANECARBOXYLIC ACID ALEMBIC LIMITED (IN) 2011-10-06 WO disclosed
WO-2007049293-A1 AN IMPROVED PROCESS FOR PREPARATION OF IRBESARTAN ALEMBIC LIMITED (IN) 2007-05-03 WO disclosed
WO-2007049293-A1 AN IMPROVED PROCESS FOR PREPARATION OF IRBESARTAN ALEMBIC LIMITED (IN) 2007-05-03 WO disclosed
EP-1751123-A1 PROCESS FOR PREPARING IRBESARTAN Dr. Reddy's Laboratories Ltd. (IN) 2007-02-14 EP disclosed
EP-1751123-A1 PROCESS FOR PREPARING IRBESARTAN Dr. Reddy's Laboratories Ltd. (IN) 2007-02-14 EP disclosed
WO-2006089927-A1 METHOD FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND (IRBESARTAN) AND ITS SYNTHESIS INTERMEDIATE INKE, S.A. (ES) 2006-08-31 WO disclosed
WO-2005113518-A1 PROCESS FOR PREPARING IRBESARTAN DR. REDDY'S LABORATORIES LTD. (IN) 2005-12-01 WO disclosed
WO-2005113518-A1 PROCESS FOR PREPARING IRBESARTAN DR. REDDY'S LABORATORIES LTD. (IN) 2005-12-01 WO disclosed
EP-0475898-A1 Azacyclic compounds CIBA-GEIGY AG (CH) 1992-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056797-A1 Process for the Preparation of Irbesartan AGTR1, REN, AGTR2 SPHK1 1145/4885EPHX2 2339/4885CNR2 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.